Tyra Biosciences (TYRA) Projected to Post Earnings on Tuesday

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) will likely be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA traded up $0.76 during mid-day trading on Friday, reaching $11.50. The company's stock had a trading volume of 1,119,937 shares, compared to its average volume of 299,056. The stock has a 50-day moving average of $13.63 and a two-hundred day moving average of $17.21. The stock has a market capitalization of $581.93 million, a P/E ratio of -7.14 and a beta of 1.09. Tyra Biosciences has a 1-year low of $9.93 and a 1-year high of $29.60.

Insiders Place Their Bets

In other news, Director Nina S. Kjellson sold 5,401 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the transaction, the director now owns 443,885 shares of the company's stock, valued at approximately $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 21,998 shares of company stock valued at $344,818 over the last 90 days. 15.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TYRA. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Tuesday, February 18th. UBS Group began coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences has an average rating of "Buy" and an average target price of $30.50.

Remove Ads

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.